Oncosuppressors and Oncogenes: Role in Haemangioma Genesis and Potential for Therapeutic Targeting

Int J Mol Sci. 2018 Apr 13;19(4):1192. doi: 10.3390/ijms19041192.

Abstract

Genetic lesions in proto-oncogenes result in the perturbation of angiogenesis, the formation of neovessels from a pre-existing microvasculature. Similarly, the subversion of tumor suppressor genes promotes tumor vascularization. Excessive neovessel formation is associated with various neoplasms such as infantile hemangiomas (IH). Hemangiomas are the most common tumors in pediatric patients and at present have no definitive treatment. The pathogenesis of IH is not well understood; however, both vasculogenesis and angiogenesis are associated with hemangioma genesis. A number of factors that modulate angiogenesis and vasculogenesis have been shown to be dysregulated in IH. Several of the oncogenes and tumor suppressors linked to the promotion of angiogenesis are also altered in infantile hemangioma. In this review, the roles of oncogenes and tumor suppressor genes during neovascularization and hemangioma genesis are explored. In addition, the potential for targeting these genes in IH therapy is discussed.

Keywords: angiogenesis; hemangioma; oncogene; oncosuppressor; vascular endothelial growth factor.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Child
  • Clinical Trials as Topic
  • Genetic Testing
  • Hemangioma / drug therapy
  • Hemangioma / genetics*
  • Humans
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / genetics
  • Oncogene Proteins / genetics*
  • Signal Transduction / drug effects
  • Tumor Suppressor Proteins / genetics*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Oncogene Proteins
  • Tumor Suppressor Proteins